- Home
- PEG vs EW Comparison
PEG vs EW Comparison
Compare PEG & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEG
- EW
- Stock Information
- Founded
- PEG 1903
- EW 1958
- Country
- PEG United States
- EW United States
- Employees
- PEG N/A
- EW N/A
- Industry
- PEG Power Generation
- EW Industrial Specialties
- Sector
- PEG Utilities
- EW Health Care
- Exchange
- PEG Nasdaq
- EW Nasdaq
- Market Cap
- PEG 42.6B
- EW 44.8B
- IPO Year
- PEG N/A
- EW 2000
- Fundamental
- Price
- PEG $81.14
- EW $80.92
- Analyst Decision
- PEG Buy
- EW Buy
- Analyst Count
- PEG 12
- EW 20
- Target Price
- PEG $92.09
- EW $85.20
- AVG Volume (30 Days)
- PEG 2.5M
- EW 3.7M
- Earning Date
- PEG 11-03-2025
- EW 10-23-2025
- Dividend Yield
- PEG 3.11%
- EW N/A
- EPS Growth
- PEG 20.00
- EW 188.09
- EPS
- PEG 3.96
- EW 7.02
- Revenue
- PEG $11,134,000,000.00
- EW $5,685,100,000.00
- Revenue This Year
- PEG $12.99
- EW $13.25
- Revenue Next Year
- PEG $4.77
- EW $9.76
- P/E Ratio
- PEG $20.48
- EW $33.86
- Revenue Growth
- PEG 8.69
- EW 9.14
- 52 Week Low
- PEG $74.67
- EW $64.01
- 52 Week High
- PEG $95.22
- EW $83.00
- Technical
- Relative Strength Index (RSI)
- PEG 35.99
- EW 56.62
- Support Level
- PEG $82.25
- EW $80.08
- Resistance Level
- PEG $82.46
- EW $82.67
- Average True Range (ATR)
- PEG 1.20
- EW 1.39
- MACD
- PEG -0.39
- EW -0.01
- Stochastic Oscillator
- PEG 12.26
- EW 65.04
About PEG Public Service Enterprise Group Incorporated
Public Service Enterprise Group is the holding company for a regulated utility (PSE&G) and PSEG Power, which owns all or a share of three nuclear plans and clean energy projects. PSE&G provides regulated gas and electricity delivery services in New Jersey to a combined 4.3 million customers. Public Service Enterprise Group also operates the Long Island Power Authority system. In 2022, the company sold its gas and oil power plants in the mid-Atlantic, New York, and the Northeast.
About EW Edwards Lifesciences Corporation
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.